Outlook Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Outlook Therapeutics

08/08/2025 18:55

Outlook Therapeutics Inc OTLK.OQ OTLK.O is expected to  show a rise in quarterly revenue when it reports  results on August 12 (estimated) for the period ending June 30 2025

The Iselin New Jersey-based  company is expected to report revenue of $1.663 million, according to the mean estimate from 4 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Outlook Therapeutics Inc is for a loss of 39 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Outlook Therapeutics Inc is $8.00, about 77% above its last closing price of $1.84

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.52
-0.60
-0.40
Beat
33.1
Dec. 31 2025
-0.69
-0.77
0.72
Beat
192.9
Sep. 30 2024
-0.86
-0.83
0.76
Beat
191.1‚Äč
Jun. 30 2024
-1.02
-1.00
-0.83
Beat
16.8
‚Äč‚ÄčMar. 31 2024
-0.96
-0.85
-1.55
Missed
-82.4
Dec. 31 2023
-0.92
-1.00
-0.80
Beat
20‚Äč
Sep. 30 2023
-1.16
-1.17
-1.00
Beat
14.9
Jun. 30 2023
-0.82
-1.03
-1.60
Missed
-55.6

This summary was machine generated August 8 at 17:55 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)